Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen.

PubWeight™: 2.37‹?› | Rank: Top 2%

🔗 View Article (PMC 2846360)

Published in Cancer Cell on March 01, 2005

Authors

Charles G Drake1, Amy D H Doody, Marianne A Mihalyo, Ching-Tai Huang, Erin Kelleher, Sowmya Ravi, Edward L Hipkiss, Dallas B Flies, Eugene P Kennedy, Meixiao Long, Patrick W McGary, Lee Coryell, William G Nelson, Drew M Pardoll, Adam J Adler

Author Affiliations

1: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA. cdrake@jhmi.edu

Articles citing this

Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol (2007) 8.31

The anticancer immune response: indispensable for therapeutic success? J Clin Invest (2008) 4.01

LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest (2007) 2.57

Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol (2010) 2.28

Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer. Prostate (2010) 2.22

Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. Cancer Cell (2011) 1.89

A novel imaging approach for early detection of prostate cancer based on endogenous zinc sensing. Cancer Res (2010) 1.79

Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs (2009) 1.71

Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice. Proc Natl Acad Sci U S A (2008) 1.60

Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. J Immunol (2009) 1.60

Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. Cancer Res (2009) 1.51

Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research. Clin Cancer Res (2011) 1.38

Regulated expression of a tumor-associated antigen reveals multiple levels of T-cell tolerance in a mouse model of lung cancer. Cancer Res (2008) 1.25

SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade. Proc Natl Acad Sci U S A (2008) 1.22

Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions. Clin Adv Hematol Oncol (2013) 1.22

Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization. Prostate (2009) 1.19

Radiotherapy augments the immune response to prostate cancer in a time-dependent manner. Prostate (2008) 1.17

Enhancing efficacy of therapeutic vaccinations by combination with other modalities. Vaccine (2007) 1.13

Prostate cancer immunotherapy. Clin Cancer Res (2011) 1.11

Castration-resistant prostate cancer: latest evidence and therapeutic implications. Ther Adv Med Oncol (2014) 1.11

Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses. Hum Immunol (2010) 1.08

Tumor recognition and self-recognition induce distinct transcriptional profiles in antigen-specific CD4 T cells. J Immunol (2009) 1.07

Current status of immunological therapies for prostate cancer. Curr Opin Urol (2010) 1.06

Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results. Clin Cancer Res (2009) 1.01

Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget (2016) 0.97

Androgens alter T-cell immunity by inhibiting T-helper 1 differentiation. Proc Natl Acad Sci U S A (2014) 0.95

Immunotherapy for prostate cancer: an emerging treatment modality. Urol Clin North Am (2010) 0.94

Dendritic cells program non-immunogenic prostate-specific T cell responses beginning at early stages of prostate tumorigenesis. Prostate (2007) 0.94

From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer. Expert Rev Vaccines (2011) 0.94

Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer. Cancer Immunol Immunother (2011) 0.93

Self-antigen prevents CD8 T cell effector differentiation by CD134 and CD137 dual costimulation. J Immunol (2008) 0.93

Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer. J Transl Med (2013) 0.93

Age-dependent tolerance to an endogenous tumor-associated antigen. Vaccine (2008) 0.92

Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy. Curr Opin Oncol (2012) 0.92

Promising novel immunotherapies and combinations for prostate cancer. Future Oncol (2009) 0.91

Androgen ablation augments human HLA2.1-restricted T cell responses to PSA self-antigen in transgenic mice. Prostate (2010) 0.91

Increased CD8+ T-cell function following castration and immunization is countered by parallel expansion of regulatory T cells. Cancer Res (2012) 0.91

Exploiting synergy: immune-based combinations in the treatment of prostate cancer. Front Oncol (2014) 0.91

In situ vaccination combined with androgen ablation and regulatory T-cell depletion reduces castration-resistant tumor burden in prostate-specific pten knockout mice. Cancer Res (2010) 0.91

iNKT cells control mouse spontaneous carcinoma independently of tumor-specific cytotoxic T cells. PLoS One (2010) 0.91

Immunotherapy for prostate cancer: recent developments and future challenges. Cancer Metastasis Rev (2014) 0.90

Unmasking the immune recognition of prostate cancer with CTLA4 blockade. Nat Rev Cancer (2012) 0.89

Complete biochemical (prostate-specific antigen) response to sipuleucel-T with enzalutamide in castration-resistant prostate cancer: a case report with implications for future research. Urology (2013) 0.89

Update on prostate cancer vaccines. Cancer J (2011) 0.88

A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment. Front Immunol (2016) 0.88

The adenosinergic immunomodulatory drugs. Curr Opin Pharmacol (2009) 0.88

Targeting the hypoxia-adenosinergic signaling pathway to improve the adoptive immunotherapy of cancer. J Mol Med (Berl) (2013) 0.87

Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances. Ther Adv Vaccines (2014) 0.86

Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview. Urol Oncol (2016) 0.86

Preclinical and clinical development of DNA vaccines for prostate cancer. Urol Oncol (2013) 0.86

Immunotherapy for metastatic prostate cancer. Urol Oncol (2007) 0.85

Shaping the repertoire of tumor-infiltrating effector and regulatory T cells. Immunol Rev (2014) 0.85

Immunotherapy in prostate cancer: emerging strategies against a formidable foe. Vaccine (2011) 0.84

Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies. Cancer J (2013) 0.84

Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications. Asian J Androl (2014) 0.84

Dendrimer nanoscaffolds for potential theranostics of prostate cancer with a focus on radiochemistry. Mol Pharm (2013) 0.84

Immunotherapy for advanced prostate cancer. Rev Urol (2007) 0.83

The current and emerging role of immunotherapy in prostate cancer. Clin Genitourin Cancer (2010) 0.83

Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation. Oncoimmunology (2013) 0.82

Proposed mechanisms of action for prostate cancer vaccines. Nat Rev Urol (2013) 0.82

Combining Vaccines with Conventional Therapies for Cancer. Update Cancer Ther (2007) 0.82

Concept and viability of androgen annihilation for advanced prostate cancer. Cancer (2014) 0.82

Anti-tumor effects of endogenous prostate cancer-specific CD8 T cells in a murine TCR transgenic model. Prostate (2011) 0.81

From bench to bedside: immunotherapy for prostate cancer. Biomed Res Int (2014) 0.81

Current status of immunological approaches for the treatment of prostate cancer. Curr Opin Urol (2012) 0.81

Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer. Expert Rev Vaccines (2011) 0.80

Tumor-associated antigens for specific immunotherapy of prostate cancer. Cancers (Basel) (2012) 0.80

T cells localized to the androgen-deprived prostate are TH1 and TH17 biased. Prostate (2011) 0.80

Inflammation in Benign Prostate Tissue and Prostate Cancer in the Finasteride Arm of the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev (2015) 0.80

The E3 ubiquitin ligase Cbl-b regulates expansion but not functional activity of self-reactive CD4 T cells. J Immunol (2009) 0.79

Immune response to sipuleucel-T in prostate cancer. Cancers (Basel) (2012) 0.79

Cancer vaccines: current directions and perspectives in prostate cancer. Curr Opin Mol Ther (2009) 0.78

Histone acetylation at the Ifng promoter in tolerized CD4 cells is associated with increased IFN-gamma expression during subsequent immunization to the same antigen. J Immunol (2007) 0.78

Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy. Cancers (Basel) (2017) 0.77

Opposing effects of androgen ablation on immune function in prostate cancer. Oncoimmunology (2012) 0.77

A high density of tertiary lymphoid structure B cells in lung tumors is associated with increased CD4(+) T cell receptor repertoire clonality. Oncoimmunology (2015) 0.77

Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier? Oncol Rev (2016) 0.76

Immune Therapy for Prostate Cancer. Cancer J (2016) 0.76

New insights into androgenic immune regulation. Oncoimmunology (2014) 0.76

Current perspectives in prostate cancer vaccines. Anticancer Agents Med Chem (2009) 0.75

Sipuleucel-T: immunotherapy for advanced prostate cancer. Open Access J Urol (2011) 0.75

Tumor-Unrelated CD4 T Cell Help Augments CD134 plus CD137 Dual Costimulation Tumor Therapy. J Immunol (2015) 0.75

Therapeutic cancer vaccine fulfills the promise of immunotherapy in prostate cancer. Immunotherapy (2011) 0.75

The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort. Oncotarget (2017) 0.75

Cytokines and metabolic factors regulate tumoricidal T-cell function during cancer immunotherapy. Immunotherapy (2017) 0.75

Androgen deprivation and immunotherapy for the treatment of prostate cancer. Endocr Relat Cancer (2017) 0.75

Articles cited by this

Molecular determinants of resistance to antiandrogen therapy. Nat Med (2003) 18.90

Cancer statistics, 2003. CA Cancer J Clin (2003) 13.46

Projection of an immunological self shadow within the thymus by the aire protein. Science (2002) 12.15

Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. Nat Immunol (2001) 12.00

Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A (1995) 8.16

Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol (1989) 7.69

Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral self. Nat Immunol (2001) 7.30

Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell (1991) 6.49

The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med (2000) 5.74

Thymic selection of CD8+ single positive cells with a class II major histocompatibility complex-restricted receptor. J Exp Med (1994) 4.91

Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc Natl Acad Sci U S A (1998) 4.53

Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response. Cell (1991) 4.38

Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature (2001) 3.99

Cytotoxic T cell recognition of the influenza nucleoprotein and hemagglutinin expressed in transfected mouse L cells. Cell (1984) 3.97

Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem (2004) 3.51

Immune tolerance after delivery of dying cells to dendritic cells in situ. J Exp Med (2002) 3.35

Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med (2000) 3.26

T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A (2001) 3.15

CD8(+) T cell-mediated spontaneous diabetes in neonatal mice. J Immunol (1996) 3.02

Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res (2000) 2.89

Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity (2000) 2.81

CD4+ T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells. J Exp Med (1998) 2.69

A history of prostate cancer treatment. Nat Rev Cancer (2002) 2.46

Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer (2003) 2.43

CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism. Immunity (1999) 2.25

Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction. J Exp Med (1998) 2.24

The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice. Mol Endocrinol (1994) 2.22

Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity (2002) 2.18

Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J Immunol (1998) 2.10

Antigen concentration and precursor frequency determine the rate of CD8+ T cell tolerance to peripherally expressed antigens. J Immunol (1999) 1.86

Maintenance of in vivo tolerance by persistence of antigen. Science (1992) 1.86

Expression of transforming growth factor-beta in the rat ventral prostate during castration-induced programmed cell death. Mol Endocrinol (1989) 1.82

Uptake of apoptotic antigen-coupled cells by lymphoid dendritic cells and cross-priming of CD8(+) T cells produce active immune unresponsiveness. J Immunol (2002) 1.79

Tolerance to islet antigens and prevention from diabetes induced by limited apoptosis of pancreatic beta cells. Immunity (2002) 1.78

Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol (2004) 1.71

Peripheral clonal elimination of functional T cells. Science (1990) 1.69

Characterization of two cis-acting DNA elements involved in the androgen regulation of the probasin gene. Mol Endocrinol (1993) 1.69

Direct evidence that functionally impaired CD4+ T cells persist in vivo following induction of peripheral tolerance. J Immunol (1998) 1.68

Morphological and histological study of castration-induced degeneration and androgen-induced regeneration in the mouse prostate. Biol Reprod (1986) 1.62

Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma. Eur J Immunol (1996) 1.49

Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. J Exp Med (2002) 1.48

T-cell tolerance toward a transgenic beta-cell antigen and transcription of endogenous pancreatic genes in thymus. Proc Natl Acad Sci U S A (1994) 1.48

CD8(+) tumor-infiltrating T cells are deficient in perforin-mediated cytolytic activity due to defective microtubule-organizing center mobilization and lytic granule exocytosis. J Immunol (2001) 1.44

Prospects for adoptive T cell therapy. Curr Opin Immunol (1997) 1.38

In vivo CD4+ T cell tolerance induction versus priming is independent of the rate and number of cell divisions. J Immunol (2000) 1.36

TGF beta in prostate cancer: a growth inhibitor that can enhance tumorigenicity. Prostate (1997) 1.30

CD4 cell priming and tolerization are differentially programmed by APCs upon initial engagement. J Immunol (2002) 1.13

Castration alters peripheral immune function in normal male mice. Immunology (1995) 1.12

Multiple components of a complex androgen-dependent enhancer. Mol Endocrinol (1991) 1.10

Effector CD4 cells are tolerized upon exposure to parenchymal self-antigen. J Immunol (2002) 1.08

The stringency and magnitude of androgen-specific gene activation are combinatorial functions of receptor and nonreceptor binding site sequences. Mol Cell Biol (1993) 1.07

Early castration reduces prostatic carcinogenesis in transgenic mice. Urology (1999) 1.07

An evaluation of the potential to use tumor-associated antigens as targets for antitumor T cell therapy using transgenic mice expressing a retroviral tumor antigen in normal lymphoid tissues. J Exp Med (1993) 1.04

PSA markers in prostate cancer detection. Urol Clin North Am (2003) 1.00

Molecular biology of the androgen receptor. Mayo Clin Proc (2000) 1.00

In vivo cyclophosphamide and IL-2 treatment impedes self-antigen-induced effector CD4 cell tolerization: implications for adoptive immunotherapy. J Immunol (2004) 0.98

Effector CD4 cell tolerization is mediated through functional inactivation and involves preferential impairment of TNF-alpha and IFN-gamma expression potentials. Cell Immunol (2003) 0.95

Clonal deletion of simian virus 40 large T antigen-specific T cells in the transgenic adenocarcinoma of mouse prostate mice: an important role for clonal deletion in shaping the repertoire of T cells specific for antigens overexpressed in solid tumors. J Immunol (2002) 0.95

Androgen-receptor gene structure and function in prostate cancer. World J Urol (1996) 0.90

Androgen ablation-induced programmed death of prostatic glandular cells does not involve recruitment into a defective cell cycle or p53 induction. Endocrinology (1995) 0.83

Studies on the prostate and testis as immunologically privileged sites. Cancer Treat Rep (1977) 0.83

Articles by these authors

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med (2012) 13.12

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86

Inflammation in prostate carcinogenesis. Nat Rev Cancer (2007) 9.08

A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med (2009) 7.45

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol (2012) 7.26

Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med (2009) 6.61

Cancer immunotherapy comes of age. J Clin Oncol (2011) 5.87

Tracking the clonal origin of lethal prostate cancer. J Clin Invest (2013) 5.79

Expression of programmed death 1 ligands by murine T cells and APC. J Immunol (2002) 5.78

Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer (2007) 5.65

Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell (2011) 5.63

Mechanisms of immune evasion by tumors. Adv Immunol (2006) 5.34

IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med (2009) 5.05

Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res (2005) 4.94

Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol (2013) 4.72

B7-H1 determines accumulation and deletion of intrahepatic CD8(+) T lymphocytes. Immunity (2004) 4.60

Role of LAG-3 in regulatory T cells. Immunity (2004) 4.36

Cutting edge: An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J Immunol (2007) 4.29

B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res (2003) 3.96

Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet (2010) 3.83

Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res (2011) 3.81

Egr-2 and Egr-3 are negative regulators of T cell activation. Nat Immunol (2005) 3.74

Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell (2009) 3.71

Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res (2012) 3.68

Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat Med (2006) 3.49

B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity (2003) 3.47

Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res (2004) 3.29

Major histocompatibility complex class II-restricted presentation of a cytosolic antigen by autophagy. Eur J Immunol (2003) 3.12

Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy. Blood (2007) 3.00

Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol (2004) 3.00

Pathological and molecular aspects of prostate cancer. Lancet (2003) 2.98

Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. Blood (2007) 2.93

Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J Exp Med (2010) 2.91

Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res (2013) 2.81

Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget (2011) 2.80

A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment. Cancer Discov (2011) 2.77

In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol (2009) 2.76

Eos mediates Foxp3-dependent gene silencing in CD4+ regulatory T cells. Science (2009) 2.76

Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res (2002) 2.71

A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood (2007) 2.69

Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction. J Exp Med (2003) 2.66

LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest (2007) 2.57

Serum estrogen, but not testosterone, levels differ between black and white men in a nationally representative sample of Americans. J Clin Endocrinol Metab (2007) 2.36

Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis (2004) 2.33

In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses. J Exp Med (2005) 2.28

Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res (2006) 2.24

Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest (2002) 2.21

Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care (2007) 2.08

DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res (2008) 2.08

T regulatory cells maintain intestinal homeostasis by suppressing γδ T cells. Immunity (2010) 2.02

An inherently bifunctional subset of Foxp3+ T helper cells is controlled by the transcription factor eos. Immunity (2013) 1.98

Lymphatic endothelial cells induce tolerance via PD-L1 and lack of costimulation leading to high-level PD-1 expression on CD8 T cells. Blood (2012) 1.95

Endotoxemia contributes to the immune paralysis in patients with cirrhosis. J Hepatol (2007) 1.90

Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptor-alpha (ER) in ER-negative human breast cancer cell lines. Cancer Biol Ther (2003) 1.88

Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. J Clin Invest (2003) 1.87

Procainamide is a specific inhibitor of DNA methyltransferase 1. J Biol Chem (2005) 1.84

Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. J Immunol (2003) 1.82

MDR1 promoter hypermethylation in MCF-7 human breast cancer cells: changes in chromatin structure induced by treatment with 5-Aza-cytidine. Cancer Biol Ther (2004) 1.82

Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjögren's syndrome. Nat Genet (2013) 1.79

High-programmed death-1 levels on hepatitis C virus-specific T cells during acute infection are associated with viral persistence and require preservation of cognate antigen during chronic infection. J Immunol (2008) 1.79

Increased protein stability causes DNA methyltransferase 1 dysregulation in breast cancer. J Biol Chem (2005) 1.79

Gleason score 6 adenocarcinoma: should it be labeled as cancer? J Clin Oncol (2012) 1.78

B7-H3 enhances tumor immunity in vivo by costimulating rapid clonal expansion of antigen-specific CD8+ cytolytic T cells. J Immunol (2004) 1.78

Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil. Is it time to move forward? Cancer Biol Ther (2008) 1.74

Cyclooxygenases in cancer: progress and perspective. Cancer Lett (2004) 1.74

Methyl-CpG binding domain protein 2 represses transcription from hypermethylated pi-class glutathione S-transferase gene promoters in hepatocellular carcinoma cells. J Biol Chem (2002) 1.72

Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol (2009) 1.71

Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res (2007) 1.71

Cutting edge: Expression of functional CD137 receptor by dendritic cells. J Immunol (2002) 1.70

Retracted Cross-linking the B7 family molecule B7-DC directly activates immune functions of dendritic cells. J Exp Med (2002) 1.68

IkappaBbeta acts to inhibit and activate gene expression during the inflammatory response. Nature (2010) 1.68

Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection. Am J Pathol (2003) 1.67

Loss-of-function of Nkx3.1 promotes increased oxidative damage in prostate carcinogenesis. Cancer Res (2005) 1.66

A role for the transcription factor Helios in human CD4(+)CD25(+) regulatory T cells. Mol Immunol (2010) 1.65

MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells. PLoS One (2010) 1.65

DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci Transl Med (2013) 1.63

Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc Natl Acad Sci U S A (2004) 1.63

Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2014) 1.61

Loss of epigenetic modification driven by the Foxp3 transcription factor leads to regulatory T cell insufficiency. Immunity (2012) 1.61

Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. J Immunol (2009) 1.60

Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells. Mol Cancer Res (2008) 1.59

GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. J Cell Biochem (2004) 1.58

Constitutive and inducible expression of b7 family of ligands by human airway epithelial cells. Am J Respir Cell Mol Biol (2005) 1.56

Does empirical treatment of community-acquired pneumonia with fluoroquinolones delay tuberculosis treatment and result in fluoroquinolone resistance in Mycobacterium tuberculosis? Controversies and solutions. Int J Antimicrob Agents (2012) 1.56

Pathological and molecular mechanisms of prostate carcinogenesis: implications for diagnosis, detection, prevention, and treatment. J Cell Biochem (2004) 1.56

Tc17 CD8 T cells: functional plasticity and subset diversity. J Immunol (2009) 1.54